Title:
PLATFORM FOR SCREENING DRUG FOR AUTOIMMUNE DISEASE ACCOMPANIED WITH INFECTIOUS DISEASE
Document Type and Number:
WIPO Patent Application WO/2024/107013
Kind Code:
A1
Abstract:
The present invention relates to a platform for screening a drug for autoimmune diseases accompanied with an infectious disease. The animal model affected by Sjögren's syndrome and COVID-19 of the present invention showed an increased inflammatory response in salivary gland tissues, compared to a Sjögren's syndrome animal model. In addition, the expression of inflammatory cytokines IL-17, IL-21, and IL-6 was increased, and the expression of the fibrosis factor α-SMA was found to be upregulated in salivary gland tissues. It was also observed that the expression of IgG2a, which is an autoimmune disease pathogenesis autoantibody, was increased, thus confirming that COVID-19 infection enhances the disease activity of Sjögren's syndrome. Additionally, systemic sclerosis immune response-activated animal models were observed to exhibit an increase in blood collagen and a significant increase in the expression of systemic sclerosis-related immune cells Th1 and Th17. The serum level of the systemic sclerosis autoantibody, which is an angiotensin2 receptor, was also found to be increased. Furthermore, damage and fibrosis in skin and lung tissues were observed to increase, and an animal model with an activated immune response in systemic sclerosis patients was successfully created. In lupus patient-mimic animal models, weight loss associated with lupus patient immunization was observed. Kidney tissue damage induced by lupus immunization and an increase in the serum amount of human IgG, an autoantibody in lupus patients, were also confirmed. Moreover, the expression of human CD8 and human CD4 in the blood was increased, and the expression of lupus pathogenesis immune cells Th1 and Th17 was elevated, verifying that the lupus patient-mimic avatar model could reflect the pathogenic lymphocytes and nephritis in lupus patients.
Inventors:
CHO MI LA (KR)
PARK SUNG-HWAN (KR)
PARK JIN SIL (KR)
JEONG HA-YEON (KR)
NA HYUN-SIK (KR)
WOO JIN SEOK (KR)
LEE SEON-YEONG (KR)
CHOI JEONG-WON (KR)
MOON YOUNG-MEE (KR)
YANG SEUNG-CHEON (KR)
LEE KUN-HEE (KR)
LEE YEON SU (KR)
PARK SUNG-HWAN (KR)
PARK JIN SIL (KR)
JEONG HA-YEON (KR)
NA HYUN-SIK (KR)
WOO JIN SEOK (KR)
LEE SEON-YEONG (KR)
CHOI JEONG-WON (KR)
MOON YOUNG-MEE (KR)
YANG SEUNG-CHEON (KR)
LEE KUN-HEE (KR)
LEE YEON SU (KR)
Application Number:
PCT/KR2023/018571
Publication Date:
May 23, 2024
Filing Date:
November 17, 2023
Export Citation:
Assignee:
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR)
International Classes:
A01K67/027; C07K14/005; G01N33/50
Foreign References:
| KR20210120705A | 2021-10-07 | |||
| KR20160116750A | 2016-10-10 | |||
| KR20200083346A | 2020-07-08 | |||
| KR20200042685A | 2020-04-24 |
Other References:
PARK MIN-JUNG, PARK YOUNGJAE; CHOI JEONG WON; BAEK JIN-AH; JEONG HA YEON; SIK HYUN; MOON YOUNG-MEE; CHO MI-LA; PARK SUNG-HWAN; ; ;: "Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin", EXPERIMENTAL AND MOLECULAR MEDICINE, NATURE PUBLISHING GROUP, GB, vol. 54, no. 9, 29 September 2022 (2022-09-29), GB , pages 1577 - 1585, XP093170273, ISSN: 2092-6413, DOI: 10.1038/s12276-022-00860-7
Attorney, Agent or Firm:
WIE, Byoung Gap (KR)
Download PDF: